Prognostic biomarkers and clinical outcomes in neuroendocrine prostate cancer (NEPC).Richard Gagnon, Steven Yip, Joseph D. Ruether et al.|Journal of Clinical Oncology|2023Cited by 3
Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC).Richard Gagnon, Steven Yip, Soufiane El Hallani et al.|Journal of Clinical Oncology|2022Cited by 0
Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self-reported social determinants of health (SDOH).Nimira Alimohamed, Steven Yip, Amanda Williams Gibson et al.|Journal of Clinical Oncology|2025Cited by 0
Gut microbiome (GMB) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair alterations (HRRm) treated with PARP inhibitor (PARPi) therapy.Steven Yip, Pinaki Bose, K. M. Tahsin Hassan Rahit et al.|Journal of Clinical Oncology|2026Cited by 0